{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:02:25Z","timestamp":1791349345653,"version":"4.3.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,5,13]],"date-time":"2015-05-13T00:00:00Z","timestamp":1431475200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12885-015-1391-x","type":"journal-article","created":{"date-parts":[[2015,5,11]],"date-time":"2015-05-11T23:52:58Z","timestamp":1431388378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report"],"prefix":"10.1186","volume":"15","author":[{"given":"Dae Won","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edelyn","family":"Barcena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urvi N","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L","family":"Rohlfs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok J","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Penas-Prado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin B","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,13]]},"reference":[{"issue":"8","key":"1391_CR1","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1634\/theoncologist.2011-0101","volume":"16","author":"G Lombardi","year":"2011","unstructured":"Lombardi G, Zustovich F, Farina P, Della Puppa A, Manara R, Cecchin D, et al. Neoplastic meningitis from solid tumors: new diagnostic and therapeutic approaches. Oncologist. 2011;16(8):1175\u201388.","journal-title":"Oncologist"},{"issue":"2","key":"1391_CR2","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/1097-0142(197808)42:2<660::AID-CNCR2820420237>3.0.CO;2-E","volume":"42","author":"MH Amer","year":"1978","unstructured":"Amer MH, Al-Sarraf M, Baker LH, Vaitkevicius VK. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer. 1978;42(2):660\u20138.","journal-title":"Cancer"},{"issue":"6","key":"1391_CR3","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1215\/15228517-2008-062","volume":"10","author":"L Harstad","year":"2008","unstructured":"Harstad L, Hess KR, Groves MD. Prognostic factors and outcomes in patients with leptomeningeal melanomatosis. Neuro Oncol. 2008;10(6):1010\u20138.","journal-title":"Neuro Oncol"},{"issue":"8","key":"1391_CR4","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/cncr.25634","volume":"117","author":"MA Davies","year":"2011","unstructured":"Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer. 2011;117(8):1687\u201396.","journal-title":"Cancer"},{"issue":"7","key":"1391_CR5","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1001\/archneur.1996.00550070064013","volume":"53","author":"M Balm","year":"1996","unstructured":"Balm M, Hammack J. Leptomeningeal carcinomatosis. Presenting features and prognostic factors. Arch Neurol. 1996;53(7):626\u201332.","journal-title":"Arch Neurol"},{"issue":"6892","key":"1391_CR6","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949\u201354.","journal-title":"Nature"},{"issue":"13","key":"1391_CR7","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1245\/s10434-012-2457-5","volume":"19","author":"S Moreau","year":"2012","unstructured":"Moreau S, Saiag P, Aegerter P, Bosset D, Longvert C, Helias-Rodzewicz Z, et al. Prognostic value of BRAF(V(6)(0)(0)) mutations in melanoma patients after resection of metastatic lymph nodes. Ann Surg Oncol. 2012;19(13):4314\u201321.","journal-title":"Ann Surg Oncol"},{"issue":"26","key":"1391_CR8","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507\u201316.","journal-title":"N Engl J Med"},{"key":"1391_CR9","doi-asserted-by":"crossref","unstructured":"Chapman PB, Hauschild A, Robert C, Larkin J, Haanen J, Ribas A. Updated overall survival results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib with dacarbazine in previously untreated patients with BRAF V600E-mutated melanoma. In: Ammerical Society of Clinical Oncology (ASCO) annual meeting. vol. 30. Chicago, Illinois; 2012: 8502.","DOI":"10.1200\/jco.2011.29.15_suppl.lba4"},{"issue":"9839","key":"1391_CR10","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358\u201365.","journal-title":"Lancet"},{"key":"1391_CR11","doi-asserted-by":"crossref","unstructured":"Hauschild A, Grob JJ, Jouary T, Gutzmer R, Millward M, Rutkowski P et al. An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). In: Americal Society of Clinical Oncology (ASCO) annual meeting vol. 31. Chicago, Illinois; 2013: 9013.","DOI":"10.1200\/jco.2013.31.15_suppl.9013"},{"issue":"11","key":"1391_CR12","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","volume":"13","author":"GV Long","year":"2012","unstructured":"Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(11):1087\u201395.","journal-title":"Lancet Oncol"},{"issue":"9","key":"1391_CR13","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1007\/s00415-012-6488-4","volume":"259","author":"I Bot","year":"2012","unstructured":"Bot I, Blank CU, Brandsma D. Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab. J Neurol. 2012;259(9):1976\u20138.","journal-title":"J Neurol"},{"issue":"1","key":"1391_CR14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000327699","volume":"4","author":"AF Hottinger","year":"2011","unstructured":"Hottinger AF, Favet L, Pache JC, Martin JB, Dietrich PY. Delayed but Complete Response following Oral Temozolomide Treatment in Melanoma Leptomeningeal Carcinomatosis. Case Rep Oncol. 2011;4(1):211\u20135.","journal-title":"Case Rep Oncol"},{"issue":"6","key":"1391_CR15","first-page":"1079","volume":"26","author":"E Pape","year":"2012","unstructured":"Pape E, Desmedt E, Zairi F, Baranzelli MC, Dziwniel V, Dubois F, et al. Leptomeningeal metastasis in melanoma: a prospective clinical study of nine patients. In Vivo. 2012;26(6):1079\u201386.","journal-title":"In Vivo"},{"issue":"8","key":"1391_CR16","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.3109\/0284186X.2011.586001","volume":"50","author":"N Schaefer","year":"2011","unstructured":"Schaefer N, Rasch K, Moehlenbruch M, Urbach H, Stuplich M, Blasius E, et al. Leptomeningeal melanomatosis: stabilization of disease due to radiation, temozolomide and intrathecal liposomal cytarabine. Acta Oncol. 2011;50(8):1260\u20132.","journal-title":"Acta Oncol"},{"issue":"11","key":"1391_CR17","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1200\/JCO.2012.46.5773","volume":"31","author":"N Schafer","year":"2013","unstructured":"Schafer N, Scheffler B, Stuplich M, Schaub C, Kebir S, Rehkamper C, et al. Vemurafenib for leptomeningeal melanomatosis. J Clin Oncol. 2013;31(11):e173\u20134.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1391_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/CMR.0b013e32835e589c","volume":"23","author":"JM Lee","year":"2013","unstructured":"Lee JM, Mehta UN, Dsouza LH, Guadagnolo BA, Sanders DL, Kim KB. Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report. Melanoma Res. 2013;23(2):175\u20138.","journal-title":"Melanoma Res"},{"issue":"1","key":"1391_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30\u20139.","journal-title":"N Engl J Med"},{"issue":"20","key":"1391_CR20","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","volume":"371","author":"GV Long","year":"2014","unstructured":"Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877\u201388.","journal-title":"N Engl J Med"},{"issue":"33","key":"1391_CR21","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1200\/JCO.2014.57.3535","volume":"32","author":"DB Johnson","year":"2014","unstructured":"Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, et al. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol. 2014;32(33):3697\u2013704.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1391_CR22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1227\/00006123-199201000-00006","volume":"30","author":"D d\u2019Avella","year":"1992","unstructured":"d\u2019Avella D, Cicciarello R, Albiero F, Mesiti M, Gagliardi ME, Russi E, et al. Quantitative study of blood-brain barrier permeability changes after experimental whole-brain radiation. Neurosurgery. 1992;30(1):30\u20134.","journal-title":"Neurosurgery"},{"issue":"3","key":"1391_CR23","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1083\/jcb.40.3.648","volume":"40","author":"MW Brightman","year":"1969","unstructured":"Brightman MW, Reese TS. Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol. 1969;40(3):648\u201377.","journal-title":"J Cell Biol"},{"issue":"6","key":"1391_CR24","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/0360-3016(90)90364-P","volume":"19","author":"DX Qin","year":"1990","unstructured":"Qin DX, Zheng R, Tang J, Li JX, Hu YH. Influence of radiation on the blood-brain barrier and optimum time of chemotherapy. Int J Radiat Oncol Biol Phys. 1990;19(6):1507\u201310.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"1391_CR25","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1200\/JCO.2006.10.0677","volume":"25","author":"ER Gerstner","year":"2007","unstructured":"Gerstner ER, Fine RL. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol. 2007;25(16):2306\u201312.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1391_CR26","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/ijc.1306","volume":"93","author":"M Demeule","year":"2001","unstructured":"Demeule M, Shedid D, Beaulieu E, Del Maestro RF, Moghrabi A, Ghosn PB, et al. Expression of multidrug-resistance P-glycoprotein (MDR1) in human brain tumors. Int J Cancer. 2001;93(1):62\u20136.","journal-title":"Int J Cancer"},{"issue":"Suppl 4","key":"1391_CR27","first-page":"S265","volume":"4","author":"E Rhun Le","year":"2013","unstructured":"Le Rhun E, Taillibert S, Chamberlain MC. Carcinomatous meningitis: Leptomeningeal metastases in solid tumors. Surg Neurol Int. 2013;4 Suppl 4:S265\u201388.","journal-title":"Surg Neurol Int"},{"issue":"2","key":"1391_CR28","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1081\/CNV-50458","volume":"23","author":"LM DeAngelis","year":"2005","unstructured":"DeAngelis LM, Boutros D. Leptomeningeal metastasis. Cancer Invest. 2005;23(2):145\u201354.","journal-title":"Cancer Invest"},{"key":"1391_CR29","doi-asserted-by":"crossref","unstructured":"Kim KB, Flaherty KT, Chapman PB, Sosman JA, Ribas A, McArthur GA et al. Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma. In: Americal Society of Clinical Oncology (ASCO) Annual Meeting. vol. 29; 2011: 8519.","DOI":"10.1200\/jco.2011.29.15_suppl.8519"},{"key":"1391_CR30","unstructured":"Amaravadi RK, Kim KB, Flaherty KT, Chapman PB, Puzanov I, Sosman JA et al: Prolonged responses to vemurafenib in patients with BRAF V600E mutant melanoma with low tumor burden at baseline. In: The Society for Melanoma Research 2011 international Congress: 2011; Tempa, Florida; 2011."},{"issue":"18","key":"1391_CR31","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1212\/WNL.0b013e3181dc1a69","volume":"74","author":"JL Clarke","year":"2010","unstructured":"Clarke JL, Perez HR, Jacks LM, Panageas KS, Deangelis LM. Leptomeningeal metastases in the MRI era. Neurology. 2010;74(18):1449\u201354.","journal-title":"Neurology"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-015-1391-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1391-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1391-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1391-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T02:48:20Z","timestamp":1599014900000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-015-1391-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,13]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1391"],"URL":"https:\/\/doi.org\/10.1186\/s12885-015-1391-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,13]]},"article-number":"400"}}